Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1061-1080 of 2,251 trials

Targeted Anti-Cancer Treatment: ProTarget Trial

We are studying how effective and safe targeted cancer drugs are for patients with advanced cancer and specific genetic markers. This research may help improve treatment options based on individual genetic profiles.

Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Prostate Cancer: Talazoparib and Enzalutamide Study

We are testing a combination of Talazoparib and Enzalutamide for patients with metastatic prostate cancer who have progressed after abiraterone. The study aims to evaluate its effectiveness and safety as a first-line treatment.

Metastatic Prostate CancerEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Head and Neck Cancer: New Treatment Combinations

We are comparing a new drug combination with a single drug for patients with locally advanced head and neck cancer. The aim is to see which treatment works better before starting chemoradiotherapy.

Locally Advanced Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vitamin C Treatment for Cardiac Surgery Patients

We are studying whether vitamin C can reduce inflammation and improve recovery in patients undergoing cardiac surgery. This trial compares vitamin C treatment to standard care to see which is more effective.

Cardiovascular Illness>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: MOST Plus Treatment Study

We are studying a new maintenance treatment for patients with advanced solid tumors to see if it helps keep the disease stable after initial therapy. This trial compares ongoing treatment with stopping the therapy to understand the best approach.

Advanced or Metastatic Cancers>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Cancer: Targeted Therapy Study

We are evaluating new treatments that specifically target the molecular changes in tumors of patients with advanced or metastatic cancer. The goal is to see how well these therapies work and their safety profile.

Advanced / Metastatic Cancers>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Hallux Valgus Surgery: Ropivacaine Ankle Block Study

We are investigating how different strengths of ropivacaine affect pain relief and recovery in patients undergoing hallux valgus repair surgery. This study aims to find the best concentration for effective anesthesia and reduced opioid use.

Bunion (Hallux Valgus)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngology

Pancreatic Cancer: Personalized FOLFIRINOX Dosing Study

We are exploring how personalized dosing of the chemotherapy drug 5-FU affects safety and treatment outcomes in pancreatic cancer patients. This study aims to find the best dosing strategy to improve effectiveness and minimize side effects.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

High-Risk Medulloblastoma: New Treatment Approaches

We are exploring whether new radiotherapy and chemotherapy methods improve outcomes for children and adults with high-risk medulloblastoma. The study also looks at the long-term effects of these treatments on patients' health and quality of life.

Medulloblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Rhabdomyosarcoma: New Treatment Combinations

We are studying new chemotherapy and radiotherapy options for children and adults with Rhabdomyosarcoma. The goal is to see if these new treatments improve outcomes compared to standard therapies.

RhabdomyosarcomaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Ovarian Cancer: 5-ALA Imaging Study

We are testing a dye called 5-ALA to see if it helps surgeons find ovarian cancer tumors that regular methods might miss. This study aims to improve tumor detection during surgery.

Ovarian Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsOncologyOtolaryngology

Kidney Transplant Rejection: INTERCEPT Study

We are studying whether adding TCZ to standard treatment helps kidney transplant recipients with chronic rejection maintain better kidney function. The trial also looks at the safety of this treatment and its effects on overall health.

Chronic Active Antibody-Mediated Rejection>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Glioma Treatment Study: Temozolomide and Lomustine

We are testing a combination of chemotherapy and radiotherapy for patients with newly diagnosed grade 2 or 3 glioma. The goal is to see if this approach improves survival compared to standard treatments.

Newly Diagnosed Glioma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Treatment

We are studying whether a combination of venetoclax and azacitidine can help clear residual disease in AML patients before a stem cell transplant. This trial also looks at the safety and effectiveness of this treatment approach.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Soft Tissue Sarcoma: Oral Cyclophosphamide vs Doxorubicin

We are comparing the effectiveness of oral cyclophosphamide and doxorubicin in treating elderly patients with advanced soft tissue sarcoma. The goal is to find out which treatment may lead to better outcomes and fewer side effects.

Soft Tissue SarcomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Zanamivir for Infants with Complicated Influenza

We are studying how safe and effective intravenous zanamivir is for hospitalized infants under 6 months with complicated influenza. This research aims to understand how the drug works in young children.

Human Influenza>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

HIV Prevention: Long-Acting Injectable Cabotegravir vs. Daily Oral Medication

We are studying whether a long-acting injectable form of cabotegravir is more effective than daily oral medication for preventing HIV in men who have sex with men. This trial aims to understand how well each option works over time and their impact on participants' health and behaviors.

HIV Prevention>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Andersen-Tawil Syndrome: Flecainide Therapy Study

We are exploring whether flecainide alone or in combination with other medications is more effective for managing heart rhythm issues in patients with Andersen-Tawil syndrome and multifocal ectopic contractions.

Andersen-Tawil SyndromeMultifocal Ectopic Purkinje-related Premature Contractions≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology